Drug intelligence / Profile preview

CAL010

Development stage: Preclinical
Lead developer: Calgent Biotechnology
Modality: Small Molecules

Overview

CAL010 is an investigational small-molecule fat-reduction agent being developed by Calgent Biotechnology. It is designed to specifically target adipocytes and adipose tissue to facilitate fat loss, making it a potential treatment for obesity and related metabolic conditions. The drug is currently in clinical development for several indications, including obesity, metabolic syndrome, type 2 diabetes, and cardiovascular diseases. While the precise molecular target within the adipose tissue has not been publicly disclosed, its primary therapeutic action is the reduction of fat mass to improve metabolic health.

Beyond the preview

Go deeper on CAL010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAL010.

Explore the full profile